Please login to the form below

Not currently logged in
Email:
Password:

David Novack leaves Novartis for Dynavax

Was global head of technical operations and supply chain for diagnostics at Swiss pharma firm

Vaccines-focused biopharma Dynavax has appointed David Novack, formerly of Novartis, to be its senior VP of operations and quality.

Novack was most recently global head of technical operations and supply chain for diagnostics at Novartis.

He also has senior vaccines experience at the pharma major, having previously served as global head of vaccine manufacturing strategy.

Prior to joining Novartis in 2006, Novack spent two years as VP, business development for vaccines company Vaxin.

From 1993 to 2004 Novack held several roles at MedImmune, working in business development, manufacturing and contract operations.

In his new role, he will support Dynavax as it prepares to advance hepatitis B vaccine Heplisav from a phase III candidate into a commercial product.

"David's background and experience will be a valuable addition to our senior management team," said president and chief medical officer, Dr Tyler Martin.

"We look forward to his contributions in the planning and implementation of a successful commercial manufacturing strategy for the advancement of Heplisav and long-term growth of the company."

In addition to Novack's appointment, Dynavax also announced that Stephen Tuck, VP, global technical operations is to step down at the end of March.

28th March 2013

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Pegasus

Pegasus inspires healthy decisions through creative, inspirational and integrated communications. Working with ambitious clients, we deliver big ideas and far-reaching...

Latest intelligence

BRIC markets
BRIC markets
Why these countries offer an opportunity for pharma despite a slowdown...
Obstetrics Virtual Journal Club: An Impetus Digital Customer Success Story
Our online solutions are not just for advisory boards - find out how one client leveraged the Impetus InSite Platform® for a virtual journal club....
Ludovic Helfgott
Novo Nordisk awakens its ‘Sleeping Beauty’
Biopharm emerges from troubled times to hit ‘solid growth’, says executive vice president Ludovic Helfgott...

Infographics